Best of BS Opinion: The antibiotics challenge, warship woes, and more

Is size an advantage for pursuing the objectives of public sector banking? What is the role of India's financial sector in achieving the $5-trillion economy target? Alokananda Chakraborty sums up.

drugs, medicines, pharma
Alokananda Chakraborty
2 min read Last Updated : Oct 02 2019 | 7:23 AM IST
From the risks associated with extending price caps on drugs to the reasons why RCEP should be at the top of India's geo-political agenda, here's a selection of Business Standard Opinion pieces for the day.

Is size an advantage for pursuing the objectives of public sector banking? What is the role of India’s financial sector in achieving the $5-trillion economy target? How ready is the Indian Navy to deal with the challenge posed by China? Alokananda Chakraborty sums up.

As the country moves to universal health care, it should move away from arbitrary price controls for drugs, argues our top edit. Read on... 

It is time for the government to set a clear road map, allocate the finances needed and facilitate the Navy in creating the capability needed for supporting India’s strategic vision in the Indo-Pacific region, says our second edit. Click here to read...

Regulation and supervision of all banks should be made ownership neutral, writes YV Reddy, a former RBI governor. Read on...

The government is taking the right steps to address the issue of high cost of funds. Greater credit discipline by
borrowers would help, writes Aditya Puri, managing director of HDFC Bank. Click here to read...

The Regional Comprehensive Economic Partnership or RCEP is undoubtedly a challenge but it's worth the effort, writes Rajeev Kher, a former commerce secretary and distinguished fellow at RIS. Read on...

There is so much demand for video content, even old movies and television shows are being repurposed for the smart phone, writes Ambi Parameswaran, independent brand strategist and founder, brand-building.com. Click here to read...

Quote of the day

“Privacy is gone, period. What we need is regulation to ensure that privacy is not exploited."
 
 Infosys co-founder S (Kris) Gopalakrishnan 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Indian Navypublic sector banksRCEPhealth careRBI GovernorIndian drug makersBS Opinion

Next Story